Anvisa's Public Meeting on E-Cigarettes in Brazil

Events by 2FIRSTS.ai

Nov.29.2023

Anvisa's Public Meeting on E-Cigarettes in Brazil

Brazil's health surveillance agency, Anvisa, is set to hold a public meeting to discuss issues surrounding e-cigarettes, according to RecordTV Brazil.

According to RecordTV Brazil, the Brazilian National Health Surveillance Agency (Anvisa) is set to hold a public meeting to discuss the issue of e-cigarettes.

References:

[1] Aplicativos de entrega de comida vendem cigarros eletrônicos ilegalmente

Also Read:

[1] Illegal Sale of E-Cigarettes in Brazil: Man Arrested with 33 Devices

[2] Brazilian police arrest 52-year-old man for illegal e-cigarette sale

#Brazil #E-cigarette #E-cigarettes and Tobacco #FIRSTUNION

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.

May.08 by 2FIRSTS.ai

BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025

BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025

British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.

Apr.28 by 2FIRSTS.ai

Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0

Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0

The Shenzhen Tobacco Monopoly Bureau recently held the city’s 2026 e-cigarette regulation work conference to implement higher-level meeting requirements, review the city’s e-cigarette regulatory work in 2025 and during the 14th Five-Year Plan period, assess the current situation, and deploy the rollout of E-cigarette Regulatory System 2.0 across Shenzhen’s tobacco commercial system.

Apr.28 by 2FIRSTS.ai

Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business

Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business

Jinjia Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 2.988 billion, up 4.57% year on year, while net profit attributable to shareholders turned to a loss of RMB 346 million. In the first quarter of 2026, revenue rose 58.13% year on year to RMB 1.005 billion, but attributable net profit fell 45.16% to RMB 36.5349 million. The company said both revenue and cost growth were related to the expansion of its new tobacco business.

Apr.28 by 2FIRSTS.ai

Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control

Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control

Ahead of World No Tobacco Day, a Nature Health Comment by Robert Beaglehole, Ruth Bonita and Tikki Pang argues that regulated smoke-free nicotine products could help accelerate the global decline in smoking. The authors propose a “smoke-free 2040” goal and call for risk-proportionate regulation distinguishing cigarettes from lower-risk nicotine alternatives.

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.

Related Topics

News Regulation

Related Read

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025

BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025

Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0

Shenzhen Tobacco Monopoly Bureau Moves to Advance E-Cigarette Regulatory System 2.0

Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business

Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business

Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control

Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications